#$%^&*AU2018201446A120180329.pdf#####ABSTRACT The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.WO 2016/174200 PCT/EP2016/059609 Figure 6 7/60 EnAd 100 NG-330-00 50 00~ -1 0 1 2 3 Log[ppc]
